Compare BioNano Genomics Inc (BNGO) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs WD 40 Company — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while WD 40 Company trades at $249.18 (market cap $3.35B). The key difference: WD 40 Company is far larger — about 253.8× BioNano Genomics Inc's market cap, and WD 40 Company pays a 1.64% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | WDFC | |
|---|---|---|
Market Cap | $13.20M | $3.35B |
Sector | Health | Technology |
52-Week High | $4.92 | $264.91 |
52-Week Low | $1.09 | $187.52 |
Enterprise Value | $15.81M | $3.40B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
WDFC trades at $251.43, down 5.09% today but maintains a bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings of $2.33 per share, beating estimates by 47%, driven by broad-based sales growth. Valuation remains elevated with a P/E of 37.88 and P/S of 5, while profitability metrics show a net income margin of 13.22% and ROE of 11%. Recent news highlights WD-40's strong brand moat and inclusion in Zacks' Strong Buy list on July 15, 2026.
Outlook is positive given earnings momentum and brand strength, but high valuation and margin pressures from input costs pose risks. Analyst consensus is mixed with 71% hold ratings, suggesting cautious optimism. The stock offers growth potential but requires monitoring of cost management and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
